Diabetes Market Growing in China
by Sam Fazeli, Director Bloomberg Industries, Europe
The diabetes market is rapidly growing in China, leading to a significant opportunity for companies with complete diabetes portfolios like Novo Nordisk and Sanofi. In addition to urbanization and obesity rates, diabetes prevalence has been fueled by the region’s aging population. The prevalence of the disease increased at a compounded annual growth rate of 12 percent in China over the past 12 years. This compares to an 8 percent CAGR globally.